Skeletal Metastases: Imaging⁹⁹ᵐTc-MDP/HDP · ¹⁸F-NaF

Quick Answer

The ⁹⁹ᵐTc-diphosphonate bone scan detects skeletal metastases by imaging the osteoblastic reaction to tumor — not the tumor cells themselves. It is sensitive and inexpensive for whole-body screening in cancers that provoke bone turnover (prostate, breast, lung), showing multiple randomly distributed asymmetric foci. Its blind spots are purely lytic or aggressive marrow-based disease (which can be normal or photopenic) and the flare phenomenon (transient increased uptake with healing). ¹⁸F-NaF PET/CT is more sensitive and specific; FDG and PSMA/DOTATATE image the tumor directly and are better for marrow-based and lytic disease.

Why the bone scan works — and where it fails

The bone scan images the osteoblastic response to a lesion, so it detects metastases that stimulate bone formation (classically prostate, sclerotic breast, many lung) as multiple, random, asymmetric foci — the hallmark pattern. Purely lytic disease (e.g. renal cell, multiple myeloma, some aggressive breast/lung) provokes little osteoblastic reaction and may be normal or photopenic (cold) — a critical false-negative. Diffuse marrow replacement can also under-call.

Patterns to recognize

Key metastatic patterns and their meaning:

The flare phenomenon

After effective systemic therapy, healing metastases transiently increase osteoblastic activity, so a follow-up scan at ~2–3 months can look worse despite response — the flare phenomenon. Judge response by comparing to later scans (or by clinical/marker trends), not by an early apparent worsening.

Choosing the modality

⁹⁹ᵐTc bone scan — cheap, available, whole-body, good for blastic disease; add SPECT/CT to characterize equivocal foci (benign vs met). ¹⁸F-NaF PET/CT — same osteoblastic mechanism but higher sensitivity/specificity and better anatomy. FDG-PET — images tumor metabolism directly; superior for lytic and marrow disease (myeloma, aggressive breast/lung) and gives whole-body staging. PSMA (prostate) and DOTATATE (NET) image the tumor target and detect marrow-based disease the bone scan misses. CT shows blastic/lytic morphology; MRI is most sensitive for marrow involvement and cord compression.

High-Yield Pearls

• The bone scan images the osteoblastic reaction, not tumor — so lytic mets can be photopenic or normal.
• Typical mets = multiple random asymmetric foci; a solitary lesion is often benign (use SPECT/CT).
• Flare = transient increased uptake with healing (~2–3 mo) — do not mistake it for progression.
• Superscan = intense skeletal uptake with absent kidneys (blastic mets or metabolic bone disease).

Common Pitfalls

• Calling a normal bone scan "no metastases" in a lytic cancer (renal, myeloma) — use FDG/MRI.
• Reading flare as progression on an early post-therapy scan.
• Over-calling a solitary degenerative or traumatic focus as a metastasis without SPECT/CT correlation.

Related Pages

• Protocol: Bone scintigraphy; tracer: ¹⁸F-NaF bone PET; patterns: Superscan, Photopenic/cold lesions, Flare phenomenon.

Differential Diagnosis

• Degenerative disease — periarticular, symmetric, joint-centered uptake (facets, shoulders, knees) is the commonest benign mimic of metastatic foci.
• Trauma/healing fractures — rib fractures in a linear, aligned ("string of beads") pattern; correlate mechanism and CT.
• Paget disease — intense uptake involving a whole bone with expansion/bowing and characteristic distribution (pelvis, spine, skull).
• Benign lesions (fibrous dysplasia, osteoid osteoma, enchondroma) presenting as focal uptake.
• Metabolic bone disease / renal osteodystrophy, which can produce a superscan mimicking diffuse blastic metastases.
• Post-therapy flare vs true progression on early follow-up scans.

Reporting Checklist

• Describe number and distribution (multiple random asymmetric axial foci favor mets; periarticular/symmetric favors degenerative).
• Flag a solitary lesion as often benign and recommend SPECT/CT or correlative imaging before calling a metastasis.
• State the lytic-cancer caveat — a normal or photopenic scan does not exclude disease in renal cell/myeloma; recommend FDG/MRI.
• Identify a superscan (diffuse uptake with faint/absent kidneys) and distinguish blastic mets from metabolic bone disease.
• On follow-up, address flare timing (transient worsening at ~2–3 months = healing) and compare later scans/markers.
• Correlate with CT for blastic vs lytic morphology and fracture risk.

Self-Check

Key References

• SNMMI/EANM bone scintigraphy and NaF PET practice guidelines.
• Reviews of skeletal-metastasis imaging comparing bone scan, NaF/FDG/PSMA PET, CT, and MRI (sensitivity by lesion type).